(Reuters) – Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer’s drug showed positive results for patients who received the highest dose. The news sent Eisai’s shares up as much as 14.6 percent in Fr... More »
We use cookies!
By using this site you agree to the use of cookies, more info.